Tacrolimus is a medication used to help prevent the body from rejecting a transplanted organ, such as a kidney. It works by weakening the immune system so that it does not attack the new organ. In this trial, tacrolimus is used as part of a treatment plan for patients who have received a kidney transplant.

MTOR Inhibitors are a type of medication that helps to prevent organ rejection after a transplant. They work by blocking a specific protein in the body that is involved in cell growth and immune response. This helps to keep the immune system from attacking the transplanted organ. In this study, MTOR inhibitors are used alongside tacrolimus to help protect the new kidney.

Mycophenolic Acid is another medication used to prevent organ rejection in people who have received a kidney transplant. It works by stopping the immune system from producing cells that can attack the new organ. In this trial, mycophenolic acid is used with tacrolimus as part of a treatment plan to help ensure the transplanted kidney is not rejected by the body.

Chronic Kidney Disease – Chronic kidney disease is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys become less effective at filtering waste and excess fluids from the blood, leading to their accumulation in the body. As the disease progresses, symptoms such as fatigue, swelling in the legs and ankles, and changes in urination patterns may occur. In advanced stages, the kidneys may fail to function adequately, necessitating dialysis or transplantation. The progression of the disease can vary, with some individuals experiencing a slow decline in kidney function, while others may progress more rapidly. Chronic kidney disease is often associated with other health conditions, such as high blood pressure and diabetes, which can further impact its progression.